Exploring considerations for the development of conceptual frameworks to support clinical outcome assessments used in medical product development
Abstract Background The Food and Drug Administration (FDA) Patient-Focused Drug Development (PFDD) Draft and Final Guidance 3 provide depictions of conceptual frameworks incorporating conceptual and measurement models for all clinical outcome assessment (COA) types; however, operational guidance for framework development is limited. Members of the International Society for Quality of Life Research (ISOQOL) Industry Special Interest Group (I-SIG) investigated current practices and perspectives to identify and disseminate key considerations for the development of conceptual frameworks to support COAs for regulatory submissions. Methodology Using an online survey of I-SIG members, the authors investigated current perspectives and practices addressing four key conceptual framework development topics: use of theoretical health/disease experience models/frameworks; conceptual model comprehensiveness; selection of COA type(s); and effective collaboration for conceptual model development. Results From 24 I-SIG survey respondents, several key considerations emerged (≥67% respondent agreement). Most respondents endorsed using published theoretical models/frameworks of health and/or behavior to support the development of conceptual models or COA strategies for clinical trials ( n = 19/24; 79%). These published models/frameworks were used to identify concepts of interest (COIs) that may be used to develop a measurement model using a COA and/or other strategy ( n = 16/19; 84%), and most respondents ( n = 18/22; 82%) recommended using a published model/framework in regulatory submissions. The majority of respondents disagreed that conceptual models should include only concepts reported “spontaneously” ( n = 19/24; 79%). Respondents determined which COI(s) warrants development of a measurement model based on each COI’s relevance to patients ( n = 16/20; 80%). The type of COA selected for evaluation of a COI depends upon the assessed COI ( n = 22/22; 100%), whether the COI is observable ( n = 21/22; 95%), characteristics of the target population ( n = 20/22; 91%), availability of existing measures ( n = 15/22; 68%), and if inclusion of more than one COA for the same COI is warranted ( n = 16/19; 84%). Finally, respondents advocated for effective conceptual model development that incorporates patient stakeholders ( n = 17/17; 100%), each with a role and commitment to capture the patient experience through their unique perspective, and healthcare professionals who regularly interact with patients ( n = 15/17; 88%). Conclusion This investigation’s guidance-generating considerations provide practical insights for developing conceptual frameworks used in medical product development.
Authors
- Natalie V. J. Aldhouse (ORCID: https://orcid.org/0000-0001-6573-7431)
- Christopher Hartford (ORCID: https://orcid.org/0000-0001-7095-0106)
- Kathleen W. Wyrwich (ORCID: https://orcid.org/0000-0002-8851-350X)
- Nicola Williamson (ORCID: https://orcid.org/0000-0002-9717-8563)
- Milena Anatchkova (ORCID: https://orcid.org/0000-0003-2035-4511)
- Maria Stoeckl Mattera
- Béatrice Tugaut (ORCID: https://orcid.org/0000-0002-6525-2845)
- Kathryn Lasch (ORCID: https://orcid.org/0000-0002-5332-2906)
- Tom Willgoss
- Michelle K. Carty
- Ana Maria Rodriguez Leboeuf
Institutions
- University of Nottingham (GB)
- Regeneron (United States) (US)
- Critical Path Institute (US)
- UCB Pharma (France) (FR)
- IQVIA (United States) (US)
- Roche (United Kingdom) (GB)
- UCB Pharma (United Kingdom) (GB)
- Thermo Fisher Scientific (United States) (US)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s41687-026-01248-1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00